title: Effects of trimetazidine on myocardial preconditioning in anesthetized rats.
abstract: Trimetazidine is a widely used anti-ischemic agent, but its effect on myocardial preconditioning in anesthetized animals has not been investigated. The aim of this study was to examine the effects of trimetazidine on ischemic preconditioning and carbachol preconditioning in anesthetized rats. Ischemic preconditioning, induced by 5-min coronary artery occlusion and 5-min reperfusion, decreased the incidence of ventricular tachycardia and abolished the occurrence of ventricular fibrillation during 30-min ischemia. Trimetazidine (10 mg/kg, i.v.) alone attenuated these parameters of arrhythmia. Carbachol infusion induced preconditioning with a marked depression of mean arterial blood pressure, heart rate and ventricular tachycardia. The marked reductions in parameters of arrhythmia induced by ischemic preconditioning and carbachol preconditioning were preserved in the presence of trimetazidine. Arrhythmia scores and myocardial infarct size were significantly reduced with ischemic preconditioning or carbachol preconditioning and were not inhibited by trimetazidine. These results show that trimetazidine protects the heart against ischemia-induced arrhythmias, reduces myocardial infarct size, preserves the effects of ischemic preconditioning and pharmacological preconditioning, and is able to mimic ischemic preconditioning in anesthetized rats.
authors.affiliation: Department of Pharmacology, Faculty of Medicine, University of Gaziantep, 27310 Gaziantep, Turkey.
authors.forename: Ali F
authors.initials: AF
authors.lastname: Kara
authors.forename: Seniz
authors.initials: S
authors.lastname: Demiryürek
authors.forename: Ahmet
authors.initials: A
authors.lastname: Celik
authors.forename: Mehmet
authors.initials: M
authors.lastname: Tarakçioğlu
authors.forename: Abdullah T
authors.initials: AT
authors.lastname: Demiryürek
mesh_terms: D000758:Anesthesia; D000818:Animals; D001145:Arrhythmias, Cardiac / Q000503:physiopathology / Q000517:prevention & control; D001794:Blood Pressure / Q000187:drug effects; D002217:Carbachol / Q000494:pharmacology; D003331:Coronary Vessels / Q000187:drug effects / Q000502:physiology; D003402:Creatine Kinase / Q000378:metabolism; D004562:Electrocardiography / Q000187:drug effects; D006339:Heart Rate / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects; D019157:Ischemic Preconditioning, Myocardial; D007527:Isoenzymes / Q000378:metabolism; D019344:Lactic Acid / Q000097:blood; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D018721:Muscarinic Agonists / Q000494:pharmacology; D009203:Myocardial Infarction / Q000473:pathology / Q000517:prevention & control; D015428:Myocardial Reperfusion Injury / Q000503:physiopathology / Q000517:prevention & control; D009206:Myocardium / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D014292:Trimetazidine / Q000494:pharmacology*; D020107:Troponin T / Q000097:blood; D014665:Vasodilator Agents / Q000494:pharmacology*
chemical_list: D007527:Isoenzymes; D018721:Muscarinic Agonists; D020107:Troponin T; D014665:Vasodilator Agents; D019344:Lactic Acid; D008315:Malondialdehyde; D002217:Carbachol; D003402:Creatine Kinase; D014292:Trimetazidine